Anti-venom Market Outlook:
Anti-venom Market size was valued at USD 1.4 billion in 2024 and is projected to reach USD 2.7 billion by the end of 2034, rising at a CAGR of 7% during the forecast period 2025-2034. In 2025, the industry size of anti-venom is evaluated at USD 1.4 billion.
The global market is aided by an underserved and large patient pool, mainly seen in low- and middle-income regions. As per the WHO report, nearly 5.8 million individuals are bitten by snakes yearly, with 2.1 to 2.9 million cases of envenoming registered and 79,970 to 137,980 deaths occurring annually. The most snake bite-affected regions are South Asia, Sub-Saharan Africa, and parts of Latin America, which have 75.6% of snake bite victims and do not have life-saving anti-venom access. Anti-venom supply chains use vital raw materials like horse or ovine plasma along with biological venom gathering, purification, lyophilization, and formulation.
The changes in the cold chain storage and regional transportation constantly delay access to the rural hospitals. The producer price index rose to 8.8% in 2023 for anti-venom products, and the consumer price index increased from 5.5% to 7.3% for anti-venom therapies in public health procurement systems. Leading manufacturers and the government are actively increasing R&D and investments in manufacturing to address the delay in supply challenges. Additionally, as per the Agency for International Development (USAID) report, funding for snakebite response and monitoring has been provided by the U.S. The trade analysis depicts the requirement of venom imports and reagents from reptile-rich regions. Global initiatives, led by WHO and backed by national ministries, seek to address these inefficiencies over the course of the next ten years by establishing regional distribution centers, localized venom collecting, and harmonized Good Manufacturing Practice (GMP) training.
